Table 2 Screening algorithm accuracy to detect 17 hHSIL+ among 764 women aged 25-69 years, after correction for missing histology outcomes
Women treated | hHSIL+ treated | Sensitivity (95%-CI) | Specificity (95%-CI) | PPV (95%-CI) | NPV (95%-CI) | ||
|---|---|---|---|---|---|---|---|
Screening approach | N | % | N | ||||
1-visit1 | |||||||
Screen-and-treat VIA | 39 | 5.1 | 7 | 41 (18 - 67) | 96 (94 - 97) | 18 (8 - 34) | 98.6 (97.5 – 99.3) |
Screen-and-treat CareHPV | 102 | 13.4 | 12 | 71 (44 - 90) | 88 (85 - 90) | 12 (6 - 20) | 99.2 (98.2 – 99.8) |
Screen-and-treat PCR | 120 | 15.7 | 15 | 88 (64 - 99) | 86 (83 - 88) | 13 (7 - 20) | 99.7 (98.9 - 100) |
2-visit2 | |||||||
Treatment based on careHPV | 89 | 11.6 | 10 | 59 (33 - 82) | 89 (87 - 92) | 11 (6 - 20) | 99.0 (97.9 – 99.6) |
Treatment based on careHPV+VIA triage3 | 22 | 2.9 | 6 | 35 (14 - 62) | 98 (97 - 99) | 27 (11 - 50) | 98.5 (97.4 – 99.3) |
Treatment based on PCR | 100 | 13.1 | 13 | 77 (50 - 93) | 88 (86 - 91) | 13 (7 - 21) | 99.4 (98.5 – 99.8) |
Treatment based on PCR + VIA triage | 20 | 2.6 | 7 | 41 (18 - 67) | 98 (97 - 99) | 35 (15 - 59) | 98.7 (97.5 – 99.4) |